Alphatec (NASDAQ:ATEC) Stock Price Down 6.5% on Insider Selling

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) dropped 6.5% on Monday following insider selling activity. The stock traded as low as $12.26 and last traded at $11.91. Approximately 437,565 shares traded hands during trading, a decline of 79% from the average daily volume of 2,038,856 shares. The stock had previously closed at $12.73.

Specifically, EVP Craig E. Hunsaker sold 13,878 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $12.36, for a total transaction of $171,532.08. Following the completion of the sale, the executive vice president now directly owns 1,450,018 shares in the company, valued at approximately $17,922,222.48. The trade was a 0.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Craig E. Hunsaker sold 186,122 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $12.34, for a total value of $2,296,745.48. Following the transaction, the executive vice president now owns 1,463,896 shares of the company's stock, valued at $18,064,476.64. This represents a 11.28% decrease in their position. The disclosure for this sale can be found here.

Wall Street Analysts Forecast Growth

ATEC has been the topic of several recent analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Piper Sandler reiterated an "overweight" rating and set a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Finally, Wall Street Zen raised shares of Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Alphatec presently has an average rating of "Moderate Buy" and an average price target of $17.89.

Alphatec Trading Down 6.1%

The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -9.28 and a beta of 1.10. The company has a fifty day simple moving average of $11.52 and a 200-day simple moving average of $10.77.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm had revenue of $169.18 million during the quarter, compared to analyst estimates of $167.57 million. During the same quarter in the previous year, the business posted ($0.34) earnings per share. The business's quarterly revenue was up 22.2% compared to the same quarter last year. On average, research analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Alphatec

Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Alphatec by 38,433.3% during the 1st quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after purchasing an additional 2,306 shares in the last quarter. Comerica Bank boosted its holdings in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after buying an additional 1,248 shares during the period. Larson Financial Group LLC bought a new stake in shares of Alphatec during the 1st quarter valued at $54,000. Quarry LP boosted its holdings in Alphatec by 79.2% in the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after purchasing an additional 2,375 shares during the period. Finally, Lazard Asset Management LLC bought a new position in Alphatec in the 4th quarter worth about $76,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.